Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of Ibuzatrelvir in Healthy Participants
NCT05580003Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ibuzatrelvir in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events up to 55 days, Laboratory Test Abnormalities up to 55 days and 10 more. Started Oct 2022; status: completed.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05580003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580003.